APRE Stock Forecast: Aprea Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Aprea Therapeutics, Inc. is $3.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Aprea Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (53): The business earns solid, repeatable profits on what it owns.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
APRE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on APRE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Ladenburg Thalmann | Initiates | Buy | $2.00 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $6.00 → $3.00 |
| 14 May 2026 | Wedbush | Maintains | Outperform | $7.00 → $6.00 |
| 7 May 2026 | Oppenheimer | Initiates | Outperform | $5.00 |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 10 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 29 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | Wedbush | Reiterates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2024 | Wedbush | Maintains | Outperform | — |
| 26 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APRE.
This page is one stock. Monday covers all of them.
APRE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
APRE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Aprea Therapeutics, Inc. returned −79.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
APRE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 914.7×
- Price / book
- 0.1×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 96% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −60.9%
- Return on assets
- −35.9%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aprea Therapeutics, Inc. has a market value of $7.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.3M.
Diluted earnings per share, trailing twelve months: −$1.08.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Aprea Therapeutics, Inc. employs 8 people.
Data provided by Twelve Data
APRE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at APRE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Aprea Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about APRE
What is the APRE stock price forecast for 2026-2027?
The median 12-month analyst price target for Aprea Therapeutics, Inc. is $3.5, with estimates ranging from $1.2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is APRE stock a buy right now?
Of the 4 analysts covering Aprea Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aprea Therapeutics, Inc. 20 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank APRE?
As at 21 Nov 2026, Aprea Therapeutics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (53 of 100).
Will APRE stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $3.5, and Ticker Nerd's factor model ranks Aprea Therapeutics, Inc. 20 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the APRE stock forecast for 2030?
No analyst covering Aprea Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $5 over the next 12 months.
How has APRE stock performed over the past year?
Aprea Therapeutics, Inc. returned -79.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aprea Therapeutics, Inc. do?
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue. Its current pipeline centers on investigational small-molecule programs, including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both being evaluated in clinical development for solid tumor indications. Aprea Therapeutics concentrates on oncology research and drug development for cancers with high unmet medical need, supporting its role in the broader market for targeted and precision medicine therapeutics. The company is headquartered in Doylestown, Pennsylvania.
CEO Dr. Oren Gilad Ph.D. · 8 employees · United States · https://aprea.com